Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
Combination of gemcitabine-cisplatin was one of the most effective chemotherapy treatment in
mesothelioma patients. However, median survival of this patient group was only about 12
months. With intent to find more effective treatment the investigators performed phase II
study with gemcitabine in low dose (130-250 mg/m2) in 6-hours (prolonged) infusion in
combination with cisplatin in advanced non-small cell lung cancer (Zwitter et al. Anticancer
Drugs 2005;16:1129-34). After favourable experience, the investigators decided to explore
such regiment in patients with malignant pleural mesothelioma (MPM) as well.
Phase:
Phase 2
Details
Lead Sponsor:
Institute of Oncology Ljubljana
Collaborator:
Ministry of Higher Education, Science and Technology, Solvenia